Linked Life Data

16635174

Source:http://linkedlifedata.com/resource/pubmed/id/16635174

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-4-25
pubmed:abstractText
In treating pediatric patients with systemic lupus erythematosus (SLE), it is necessary to quickly attain remission to avoid sequelae in various organs and to maintain it over a long period. However, to maintain remission, the prolonged use of immunosuppressants which have various adverse effects, is often necessary in addition to steroids, and complications due to such immunosuppressants pose very important problems. A regimen of mizoribin (MZR) at 150 mg/day divided into two or three doses has been recommended, but while this regimen has been safe, its efficacy has not been satisfactory. However, MZR produces effects dose-dependently, and the dose recommended to date may have been insufficient for the treatment of children with SLE.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1328-8067
pubmed:author
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
152-7
pubmed:dateRevised
2008-5-21
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
High-dose mizoribine treatment for adolescents with systemic lupus erythematosus.
pubmed:affiliation
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan. nozu@med.kobe-u.ac.jp
pubmed:publicationType
Journal Article, Case Reports